Real‐World Use of Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs in Patients With Axial Spondyloarthritis in the United States: Persistence, Variables Associated With Persistence, and Dosing Variations

• Maureen DubreuilBoston University
• Jessica A. WalshUniversity of Utah
• Atul A. DeodharOregon Health & Science University
• Lianne S. GenslerUniversity of California, San Francisco
• Jeffrey R. CurtisUniversity of Alabama at Birmingham
• Sarah WelbyUCB Pharma (Belgium)
• Olga PilipczukUCB Pharma (Belgium)
• Silky Beaty
• Michael Frank MørupUniversity of Copenhagen
• V. TaiebUCB Pharma (France)
• Suzanne B. Anjohrin